Cover Image
市場調查報告書

抗性綠色膿菌感染疾病:開發平台分析

Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 321921
出版日期 內容資訊 英文 43 Pages
訂單完成後即時交付
價格
Back to Top
抗性綠色膿菌感染疾病:開發平台分析 Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H1 2017
出版日期: 2017年04月28日 內容資訊: 英文 43 Pages
簡介

綠膿菌對宿主抵抗力弱的患者而言是造成感染的重要原因。這個菌種具有對各種抗生物質急速產生抗藥性的能力。此外更是入院一週以上的患者最常分離出的病原體。症狀有肺炎、發燒、疲勞感、會發癢的疹子、出血性潰瘍、頭痛等。危險因子有高齡化及身體衰弱免疫系統低落等。

本報告提供抗性綠色膿菌感染疾病的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,以及最新的新聞和發表等訊息。

簡介

  • 調查範圍

抗性綠色膿菌感染疾病:開發平台分析 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Achaogen Inc.
  • AstraZeneca Plc
  • Biolytics Pharma
  • CSA Biotechnologies LLC
  • LegoChem Biosciences, Inc
  • Melinta Therapeutics, Inc
  • Phico Therapeutics Limited
  • Phylogica Limited
  • 鹽野義製藥
  • Zambon Company S.p.A.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ACHN-975 Prodrug
  • 綠色膿菌感染疾病生技藥品
  • CSA-13
  • G-10
  • LCB-010200
  • LCB-100200
  • 革蘭氏陰性菌感染疾病的單株抗體
  • PT-3.33
  • RXP-763
  • RXP-766
  • RXP-770
  • RXP-792
  • RXP-793
  • RXP-808
  • RXP-873
  • S-649266
  • 多重抗藥性菌感染疾病小分子
  • 抗性綠色膿菌感染疾病用小分子
  • 革蘭氏陰性菌感染疾病LpxC抑制劑
  • ZP-046

最近的開發平台趨勢

暫停中的計劃

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9195IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H1 2017, provides an overview of the Resistant Pseudomonas aeruginosa Infections (Infectious Disease) pipeline landscape.

Pseudomonas aeruginosa has become an important cause of infection, especially in patients with compromised host defense mechanisms. It has an ability to rapidly develop resistance to multiple classes of antibiotics. It is the most common pathogen isolated from patients who have been hospitalized for more than one week. Signs and symptoms include pneumonia, fever, fatigue, itchy rash, bleeding ulcers and headache. Risk factors include age and weakened immune system.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Resistant Pseudomonas aeruginosa Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Resistant Pseudomonas aeruginosa Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Resistant Pseudomonas aeruginosa Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 6 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Resistant Pseudomonas aeruginosa Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Resistant Pseudomonas aeruginosa Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Resistant Pseudomonas aeruginosa Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Resistant Pseudomonas aeruginosa Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Resistant Pseudomonas aeruginosa Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Resistant Pseudomonas aeruginosa Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Resistant Pseudomonas aeruginosa Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Resistant Pseudomonas aeruginosa Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Resistant Pseudomonas aeruginosa Infections - Overview
    • Resistant Pseudomonas aeruginosa Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Resistant Pseudomonas aeruginosa Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Resistant Pseudomonas aeruginosa Infections - Companies Involved in Therapeutics Development
    • Achaogen Inc
    • Biolytics Pharma
    • LegoChem Biosciences Inc
    • Melinta Therapeutics Inc
    • Shionogi & Co Ltd
  • Resistant Pseudomonas aeruginosa Infections - Drug Profiles
    • Biologic for Multi-Drug Resistant Pseudomonas aeruginosa Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic for Pseudomonas Aeruginosa Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic for Resistant Pseudomonas aeruginosa Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cefiderocol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSA-13 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • G-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMT-504 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LCB-100200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies for Gram-Negative Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit PcrV for Resistant Pseudomonas aeruginosa Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RXP-873 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Resistant Pseudomonas aeruginosa Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit LpxC for Gram Negative Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections and Respiratory Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Resistant Pseudomonas aeruginosa Infections - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Resistant Pseudomonas aeruginosa Infections, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Resistant Pseudomonas aeruginosa Infections - Pipeline by Achaogen Inc, H1 2017
  • Resistant Pseudomonas aeruginosa Infections - Pipeline by Biolytics Pharma, H1 2017
  • Resistant Pseudomonas aeruginosa Infections - Pipeline by LegoChem Biosciences Inc, H1 2017
  • Resistant Pseudomonas aeruginosa Infections - Pipeline by Melinta Therapeutics Inc, H1 2017
  • Resistant Pseudomonas aeruginosa Infections - Pipeline by Shionogi & Co Ltd, H1 2017
  • Resistant Pseudomonas aeruginosa Infections - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Resistant Pseudomonas aeruginosa Infections, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top